Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amgen Inc's Subsidiary Receives U.S. FDA Approval For NEXAVAR (sorafenib)


Friday, 22 Nov 2013 05:30pm EST 

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen Inc subsidiary announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment. NEXAVAR was approved following a priority review by the FDA, a designation reserved for drugs that may offer a improvement in treatment over existing options. 

Company Quote

147.26
0.01 +0.01%
24 Oct 2014